R.PR
REGISTERED-PRINCIPAL REGISTER
05/04/2022
Voltar para busca
Dado oficial do USPTO
TEON
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
05/04/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
04/10/2018
Data de registro
05/04/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/04/2022
Última transação
05/04/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
18/02/2022
Primeiro uso no comércio
18/02/2022
Código do desenho
4
Tipo de titular
03
Localização do titular
Redwood City, CA
Examinador
ORNDORFF, LINDA
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Teon Therapeutics, Inc.
Representantes
Michelle D. Kahn Sheppard Mullin
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatologicalcardiovascularhematologicalbonerespiratorycentral nervous systemendocrinologicalcirculatorygastroenterologicaldigestivehormonaldiabeticmuscularrheumaticimmune systemocular and metabolic diseases and disorders; pharmaceuticals for treating acromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic pain; pharmaceutical preparations for use in immunologyoncology including immuno-oncologycardiovascular and metabolic diseasesinfectious diseases; pharmaceuticals designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseasesincluding cancerautoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivityrespiratory diseasesgastrointestinal diseasescardiovascular and metabolic diseasespathogen infectionsmusculoskeletal diseasesophthalmologic and dermatologic diseasesgenitourinary diseasesdegenerative diseasesorphan diseases; protein therapeuticspharmaceutical preparations for use in immunology including rheumatologyoncology including immuno-oncologypulmonologygastroenterologyendocrinologydermatologyurologygynecology including fertilityinfectiology including virologyophthalmologyhepatologyneurologygeriatrics; protein therapeuticsproteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseasesincluding cancer and autoimmune disorderscytokinesinterferonstumor cell targeting and cytolytic agentstolerogenic and antiallergic factorsgrowth and differentiation factorshormonesreplacement enzymescoagulation factorslipid binding proteinsprotein factors for manufacturing of adoptive cell therapy productsanti-infectivespain killerstissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areasprotein arrays for medical diagnosis purposes; pharmaceutical preparationssynthetic proteins for use in immunology including rheumatologyoncology including immuno-oncologypulmonologygastroenterologyendocrinologydermatologyurologygynecology including fertilityinfectiology including virologyophthalmologyhepatologyneurologygeriatrics
Classe 42
Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating acromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic pain; medical research for the treatment or prevention of dermatologicalcardiovascularhematologicalbonerespiratorycentral nervous systemendocrinologicalcirculatorygastroenterologicaldigestivehormonaldiabeticmuscularrheumaticimmune systemocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific researchconducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatologyoncology including immuno-oncologypulmonologygastroenterologyendocrinologydermatologyurologygynecology including fertilityinfectiology including virologyophthalmologyhepatologyneurologygeriatricslaboratory medicineclinical diagnosticsgenetics and phenomicspathology and forensicsproteomicsveterinary medicine and diagnosticsbasic research tools; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical researchresearch relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical researchresearch relating to synthetic proteins for use in connection with a wide variety of therapeutic agents
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
26/02/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
25/02/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
22/02/2022
IUAF
USE AMENDMENT FILED
18/02/2022
EISU
TEAS STATEMENT OF USE RECEIVED
18/02/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
23/10/2021
EX5G
SOU EXTENSION 5 GRANTED
22/10/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
22/10/2021
EXT5
SOU EXTENSION 5 FILED
14/10/2021
EEXT
SOU TEAS EXTENSION RECEIVED
14/10/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/04/2021
EX4G
SOU EXTENSION 4 GRANTED
16/04/2021
EXT4
SOU EXTENSION 4 FILED
16/04/2021
EEXT
SOU TEAS EXTENSION RECEIVED
16/04/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/04/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/04/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/04/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
26/09/2020
EX3G
SOU EXTENSION 3 GRANTED
24/09/2020
EXT3
SOU EXTENSION 3 FILED
24/09/2020
EEXT
SOU TEAS EXTENSION RECEIVED
24/09/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/04/2020
EX2G
SOU EXTENSION 2 GRANTED
20/04/2020
EXT2
SOU EXTENSION 2 FILED
20/04/2020
EEXT
SOU TEAS EXTENSION RECEIVED
20/04/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/10/2019
EX1G
SOU EXTENSION 1 GRANTED
27/09/2019
EXT1
SOU EXTENSION 1 FILED
27/09/2019
EEXT
SOU TEAS EXTENSION RECEIVED
27/09/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
23/04/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/02/2019
PUBO
PUBLISHED FOR OPPOSITION
26/02/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/01/2019
DOCK
ASSIGNED TO EXAMINER
16/01/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/10/2018
NWAP
NEW APPLICATION ENTERED
08/10/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TEON ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.